Joseph P. Connor, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Joseph P. Connor completed his medical degree at the University of Cincinnati College of Medicine. He received residency training in Obstetrics and Gynecology at Northwestern University followed by sub- specialty fellowship training in Gynecologic Oncology at the University of Iowa. He is a physician-scientist whose primary research focus is on immune mechanisms of disease as it relates to gynecologic cancers. Dr. Connor is currently a member of the UW Carbone Cancer Center's Experimental Therapeutics Program. He is the Director of the UWCCC Gynecologic Cancer Disease-Oriented Working Group. This group works on research efforts to treat female pelvic cancers.
UW School of Medicine and Public Health
|Department of Pathology and Laboratory Medicine|
Professional Certifications and Education
Obstetrics & Gynecology
Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
Northwestern Memorial Hospital, Chicago, IL
University of Cincinnati Medical Center, Cincinnati, OH
University of Cincinnati College of Medicine, Cincinnati, OH
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Dr. Connor is the primary investigator on two current clinical trials of novel immune based therapies for gynecologic cancers. He is also co-investigator on several grants with Dr. Manish Patankar, a PhD scientist in the Cancer Center. His main research interests are: the development of immunotherapy for gynecologic malignancies via phase I and phase II clinical trials, both investigator-initiated and via the Gynecologic Oncology Group; mechanisms of immune evasion in cancer; and improving the clinical use of the CA125 blood test for ovarian cancer by researching the function of CA125 in ovarian cancer - in particular, CA125's effects on immune cell function in women with ovarian cancer and its ability to facilitate metastasis by interaction with other cancer-associated molecules that allow attachment of ovarian tumor cells.